BBIO as reported
BridgeBio Pharma, Inc. reported $713M of revenue over the trailing twelve months, +202% on the year before. 10 reported series are charted on this page, each one as filed.
$713M
Revenue, trailing twelve months · to Q2 2026 · +202% against the twelve months before
- Net Income
- −$702M
Net Income · −11% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- −$435M
Free Cash Flow · −34% year on year · trailing twelve months to Q2 2026
- Op Margin
- −77%
Op Margin · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $713M | +202% | Q2 2026 |
| Net Income | −$702M | −11% | Q2 2026 |
| EPS | −$3.56 | −13% | Q2 2026 |
| Gross Margin | 95% | n/a | Q2 2026 |
| Op Margin | −77% | n/a | Q2 2026 |
| Net Margin | −107% | n/a | Q2 2026 |
| ROE | 34% | n/a | Q2 2026 |
| ROA | −67% | n/a | Q2 2026 |
| ROIC | 72% | n/a | Q2 2026 |
| Free Cash Flow | −$435M | −34% | Q2 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
BridgeBio Pharma, Inc. (BBIO) - Revenue & ProfitRevenue & ProfitBridgeBio Pharma, Inc. (BBIO)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com